Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Medical Case Reports
Published in: Journal of Medical Case Reports 1/2012

Open Access 01-12-2012 | Case report

Response to sunitinib in combination with proton beam radiation in a patient with chondrosarcoma: a case report

Authors: Jennifer Dallas, Iman Imanirad, Rajiv Rajani, Roi Dagan, Sukanthini Subbiah, Rebecca Gaa, Wayne A Dwarica, Alison M Ivey, Robert A Zlotecki, Robert Malyapa, Daniel J Indelicato, Mark T Scarborough, John D Reith, C Parker Gibbs, Long H Dang

Published in: Journal of Medical Case Reports | Issue 1/2012

Login to get access

Abstract

Introduction

Chondrosarcoma is well-known to be primarily resistant to conventional radiation and chemotherapy.

Case presentation

We present the case of a 32-year-old Caucasian man with clear cell chondrosarcoma who presented with symptomatic recurrence in his pelvis and metastases to his skull and lungs. Our patient underwent systemic therapy with sunitinib and then consolidation with proton beam radiation to his symptomatic site. He achieved complete symptomatic relief with a significantly improved performance status and had an almost complete and durable metabolic response on fluorine-18-fluorodeoxyglucose positron emission tomography.

Conclusions

Our findings have important clinical implications and suggest novel clinical trials for this difficult to treat disease.
Appendix
Available only for authorised users
Literature
1.
Gelderblom H, Hogendoorn PC, Dijkstra SD, van Rijswijk CS, Krol AD, Taminiau AH, Bovee JV: The clinical approach towards chondrosarcoma. Oncologist. 2008, 13: 320-329. 10.1634/theoncologist.2007-0237.CrossRefPubMed
2.
Chow WA: Update on chondrosarcomas. Curr Opin Oncol. 2007, 19: 371-376. 10.1097/CCO.0b013e32812143d9.CrossRefPubMed
3.
Onishi AC, Hincker AM, Lee FY: Surmounting chemotherapy and radioresistance in chondrosarcoma: molecular mechanisms and therapeutic targets. Sarcoma. 2011, 2011: 381564-CrossRefPubMed
4.
Riedel RF, Larrier N, Dodd L, Kirsch D, Martinez S, Brigman BE: The clinical management of chondrosarcoma. Curr Treat Options Oncol. 2009, 10: 94-106. 10.1007/s11864-009-0088-2.CrossRefPubMed
5.
Weber KL, Pring ME, Sim FH: Treatment and outcome of recurrent pelvic chondrosarcoma. Clin Orthop Relat Res. 2002, 397: 19-28.CrossRefPubMed
6.
Grignani G, Palmerini E, Stacchiotti S, Boglione A, Ferraresi V, Frustaci S, Comandone A, Casali PG, Ferrari S, Aglietta M: A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-alpha or -beta: An Italian Sarcoma Group study. Cancer. 2011, 117: 826-831. 10.1002/cncr.25632.CrossRefPubMed
7.
Chao J, Budd GT, Chu P, Frankel P, Garcia D, Junqueira M, Loera S, Somlo G, Sato J, Chow WA: Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. Anticancer Res. 2010, 30: 547-552.PubMed
8.
Katz D, Lazar A, Lev D: Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways. Expert Rev Mol Med. 2009, 11: e30-CrossRefPubMed
9.
Trojan A, Montemurro M, Kamel M, Kristiansen G: Successful PDGFR-{alpha}/{beta} targeting with imatinib in uterine sarcoma. Ann Oncol. 2009, 20: 1898-1899. 10.1093/annonc/mdp431.CrossRefPubMed
10.
Dewaele B, Floris G, Finalet-Ferreiro J, Fletcher CD, Coindre JM, Guillou L, Hogendoorn PC, Wozniak A, Vanspauwen V, Schoffski P, Marynen P, Vandenberghe P, Sciot R, Debiec-Rychter M: Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma. Cancer Res. 2010, 70: 7304-7314. 10.1158/0008-5472.CAN-10-1543.CrossRefPubMed
11.
George S, Merriam P, Maki RG, van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan ML: Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009, 27: 3154-3160. 10.1200/JCO.2008.20.9890.CrossRefPubMedPubMedCentral
12.
Taniguchi E, Nishijo K, McCleish AT, Michalek JE, Grayson MH, Infante AJ, Abboud HE, Legallo RD, Qualman SJ, Rubin BP, Keller C: PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene. 2008, 27: 6550-6560. 10.1038/onc.2008.255.CrossRefPubMedPubMedCentral
13.
Shimizu A, O'Brien KP, Sjoblom T, Pietras K, Buchdunger E, Collins VP, Heldin CH, Dumanski JP, Ostman A: The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 1999, 59: 3719-3723.PubMed
14.
McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA: Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005, 23: 866-873. 10.1200/JCO.2005.07.088.CrossRefPubMed
15.
Lagonigro MS, Tamborini E, Negri T, Staurengo S, Dagrada GP, Miselli F, Gabanti E, Greco A, Casali PG, Carbone A, Pierotti MA, Pilotti S: PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma. J Pathol. 2006, 208: 615-623. 10.1002/path.1945.CrossRefPubMed
16.
Schrage YM, Briaire-de Bruijn IH, de Miranda NF, van Oosterwijk J, Taminiau AH, van Wezel T, Hogendoorn PC, Bovee JV: Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res. 2009, 69: 6216-6222. 10.1158/0008-5472.CAN-08-4801.CrossRefPubMed
17.
Papaetis GS, Syrigos KN: Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs. 2009, 23: 377-389. 10.2165/11318860-000000000-00000.CrossRefPubMed
18.
Christensen JG: A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol. 2007, 18 (Suppl 10): x3-10.CrossRefPubMed
19.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007, 356: 115-124. 10.1056/NEJMoa065044.CrossRefPubMed
20.
Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006, 368: 1329-1338. 10.1016/S0140-6736(06)69446-4.CrossRefPubMed
21.
Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G, Hallahan DE: SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 2003, 63: 4009-4016.PubMed
22.
Kao J, Packer S, Vu HL, Schwartz ME, Sung MW, Stock RG, Lo YC, Huang D, Chen SH, Cesaretti JA: Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer. 2009, 115: 3571-3580. 10.1002/cncr.24412.CrossRefPubMedPubMedCentral
Metadata
Title
Response to sunitinib in combination with proton beam radiation in a patient with chondrosarcoma: a case report
Authors
Jennifer Dallas
Iman Imanirad
Rajiv Rajani
Roi Dagan
Sukanthini Subbiah
Rebecca Gaa
Wayne A Dwarica
Alison M Ivey
Robert A Zlotecki
Robert Malyapa
Daniel J Indelicato
Mark T Scarborough
John D Reith
C Parker Gibbs
Long H Dang
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2012
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/1752-1947-6-41

Other articles of this Issue 1/2012

Journal of Medical Case Reports 1/2012 Go to the issue

Case report

A minimally invasive technique for closing an iatrogenic subclavian artery cannulation using the Angio-Seal closure device: two case reports

Case report

Gamma Knife® radiosurgery for recurrent intracranial olfactory neuroblastoma (esthesioneuroblastoma): a case report

Case report

Intramedullary spinal cord metastasis from prostate carcinoma: a case report

Case report

Acute fulminant pseudomembranous colitis which developed after ileostomy closure and required emergent total colectomy: a case report

Case report

Hypoparathyroidism in an Egyptian child with Hutchinson-Gilford progeria syndrome: a case report

Case report

Nonossifying fibroma presenting as an aneurysmal bone cyst: a case report